Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 in Patients with Advanced or Metastatic Solid Tumors

MC #23-23

NCT #
not yet registered
Condition(s)
Solid Tumor
Molecular Target(s)
CD137, PD-L1
Drug Classification(s)
Bispecific Antibodies
Agents(s)
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway. 
Phase(s)
I

Mechanism of Action

BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody

Purpose

  • How much of the study can be given with an acceptable level of side effects
  • The effects of the study (good and bad)
  • How much of the study is absorbed into the blood and how fast it is removed
  • How the study is acting on your body

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.